Literature DB >> 10319883

Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype.

R Krüger1, A M Vieira-Saecker, W Kuhn, D Berg, T Müller, N Kühnl, G A Fuchs, A Storch, M Hungs, D Woitalla, H Przuntek, J T Epplen, L Schöls, O Riess.   

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative disorders affecting about 1% of Western populations older than age 50. The pathological hallmark of PD are Lewy bodies, that is, intracytoplasmic inclusion bodies in affected neurons of the substantia nigra. Recently, alpha-synuclein (alpha-SYN) has been identified as the main component of Lewy bodies in sporadic PD, suggesting involvement in neurodegeneration via protein accumulation. The partially overlapping pathology of PD and Alzheimer's disease, as well as striking structural similarities of alpha-SYN and apolipoprotein E, which is a major risk factor for late-onset Alzheimer's disease, prompted us to investigate the influence of different alpha-SYN and apolipoprotein E alleles for developing sporadic PD. We performed association studies in 193 German PD patients and 200 healthy control subjects matched for age, sex, and origin. A polymorphism in the promoter region of the alpha-SYN gene (NACP-Rep1) as well as of the closely linked DNA markers D4S1647 and D4S1628 revealed significant differences in the allelic distributions between PD patients and the control group. Furthermore, the Apo epsilon4 allele but not the Th1/E47 promoter polymorphism of the apolipoprotein E gene was significantly more frequent among early-onset PD patients (age at onset, <50 years) than in late-onset PD. Regarding the combination of the Apo epsilon4 allele and allele 1 of the alpha-SYN promoter polymorphism, a highly significant difference between the group of PD patients and control individuals has been found, suggesting interactions or combined actions of these proteins in the pathogenesis of sporadic PD. PD patients harboring this genotype have a 12.8-fold increased relative risk for developing PD during their lives.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10319883     DOI: 10.1002/1531-8249(199905)45:5<611::aid-ana9>3.0.co;2-x

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  74 in total

1.  SNCA variant associated with Parkinson disease and plasma alpha-synuclein level.

Authors:  Ignacio F Mata; Min Shi; Pinky Agarwal; Kathryn A Chung; Karen L Edwards; Stewart A Factor; Douglas R Galasko; Carmen Ginghina; Alida Griffith; Donald S Higgins; Denise M Kay; Hojoong Kim; James B Leverenz; Joseph F Quinn; John W Roberts; Ali Samii; Katherine W Snapinn; Debby W Tsuang; Dora Yearout; Jing Zhang; Haydeh Payami; Cyrus P Zabetian
Journal:  Arch Neurol       Date:  2010-11

2.  Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease.

Authors:  Ziv Gan-Or; Anat Bar-Shira; Tanya Gurevich; Nir Giladi; Avi Orr-Urtreger
Journal:  Neurogenetics       Date:  2011-08-12       Impact factor: 2.660

3.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.

Authors:  K A Conway; S J Lee; J C Rochet; T T Ding; R E Williamson; P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 4.  Neurodegenerative disorders: Parkinson's disease and Huntington's disease.

Authors:  S M Hague; S Klaffke; O Bandmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

5.  Exploring gene-environment interactions in Parkinson's disease.

Authors:  Colin C McCulloch; Denise M Kay; Stewart A Factor; Ali Samii; John G Nutt; Donald S Higgins; Alida Griffith; John W Roberts; Berta C Leis; Jennifer S Montimurro; Cyrus P Zabetian; Haydeh Payami
Journal:  Hum Genet       Date:  2008-01-22       Impact factor: 4.132

6.  Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.

Authors:  Stewart A Factor; N Kyle Steenland; Donald S Higgins; Eric S Molho; Denise M Kay; Jennifer Montimurro; Ami R Rosen; Cyrus P Zabetian; Haydeh Payami
Journal:  Mov Disord       Date:  2011-06-28       Impact factor: 10.338

Review 7.  The genetics of Parkinson's disease: progress and therapeutic implications.

Authors:  Andrew B Singleton; Matthew J Farrer; Vincenzo Bonifati
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

Review 8.  The genetics of Parkinson's disease.

Authors:  Kah Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 9.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

10.  Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease.

Authors:  Shuwen Cao; Shaji Theodore; David G Standaert
Journal:  Mol Neurodegener       Date:  2010-10-26       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.